Gujarat Themis Biosyn Ltd.
Fundamentals
- Market cap
- ₹4,246 cr
- P/E
- 90.95×
- ROE
- 19.64%
- Debt / equity
- 0.12
- Div yield
- 0.17%
- 52-week range
- 225.75 — 479.45
Company snapshot
Gujarat Themis Biosyn Ltd.
Pharmaceuticals
₹4,277 cr
P/E 91.62×
Latest quarter · Mar 2026
Sales₹44 cr
Net profit₹11 cr
Op. margin+43.8%
EPS₹1.00
Strength & growth
Debt / equity0.12×
Current ratio1.84×
Sales CAGR+17.6%
EPS CAGR+26.0%
The timeline — 5 notes on Gujarat Themis Biosyn Ltd.
June 2026
- 06 Jun 26 · 7:19 PM IST Alert Alert · Small cap
Gujarat Themis will dilute a fifth of itself for a ¥21.5bn Japan deal
A ₹1,000 cr QIP and a separate preferential issue will fund the MicroBiopharm Japan acquisition.
- 03 Jun 26 · 6:14 PM IST Brief Brief · Small cap
Gujarat Themis Biosyn to raise equity for ¥21.5 bn Japan deal
The board will meet June 6 to decide on a QIP, preferential allotment, or other equity route. The raise will fund last month's ¥21.5 bn acquisition of MicroBiopharm Japan.
May 2026
- 25 May 26 · 3:09 PM IST Brief Brief · Small cap
Gujarat Themis Biosyn plans a cash raise. It hasn't named the price or the buyer.
FY26 results are routine. The board's separate approval for a preferential equity issue to non-promoters is not.
- 22 May 26 · 8:39 PM IST Alert Alert · M&A · Small cap
Gujarat Themis Biosyn bets ₹1,300 cr to buy Japan's MicroBiopharm
The deal is valued at 33% of the company's market cap and aims to shift its focus from intermediates to high-tech CDMO services.